To address the critical need for early diagnosis of Alzheimer’s disease (AD) and the prevention of severe symptoms, we have enhanced the SPCE devices by incorporating nanostructures to quantify Aβ42 and ApoE4 in blood samples with a high sensitivity, as illustrated in Figure 1. The gene discussed is APOE; the disease is early-onset autosomal dominant Alzheimer disease.